Akanda Corp
NASDAQ:AKAN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (13.2), the stock would be worth $106.79 (773% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.5 | $12.23 |
0%
|
| 3-Year Average | 13.2 | $106.79 |
+773%
|
| 5-Year Average | 14.2 | $114.29 |
+834%
|
| Industry Average | 0.1 | $0.51 |
-96%
|
| Country Average | 0 | $0.18 |
-99%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
A
|
Akanda Corp
NASDAQ:AKAN
|
6.5m USD | 1.5 | -1.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 31.5 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 6.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 5.9 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 5.9 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 5.3 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 6 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 1.8 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 6.4 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 49 422.3 |
Other Multiples
Akanda Corp
Glance View
Akanda Corp. engages in cultivating cannabis. The firm is engaged in the cultivation, manufacturing, and distribution of cannabis. The firm cultivate and process natural cannabis at its facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower and cannabis concentrates to wholesalers in international markets. The firm also import and sell medical cannabis-based products to the domestic market in the United Kingdom. The Company’s subsidiaries include Bophelo Bio Science and Wellness (Pty) Limited, Canmart Limited, Bophelo Holdings Limited, and Cannahealth Limited. Bophelo Bio Science and Wellness (Pty) Limited is focused on the cultivation of cannabis, the production of medical cannabis products including dried flower, oils, and other concentrates. Canmart Limited is engaged in the production and sale of cannabis-based products for medicinal use.
